Aquestive Therapeutics (AQST) stock price, revenue, and financials

Aquestive Therapeutics market cap is $170.9 m, and annual revenue was $52.61 m in FY 2019

$170.9 M

AQST Mkt cap, 27-May-2020

$8.8 M

Aquestive Therapeutics Revenue Q1, 2020
Aquestive Therapeutics Net income (Q1, 2020)-16.5 M
Aquestive Therapeutics EBIT (Q1, 2020)-13.9 M
Aquestive Therapeutics Cash, 31-Mar-202035.5 M
Aquestive Therapeutics EV200.4 M

Aquestive Therapeutics Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

51.8m66.9m67.4m52.6m

Revenue growth, %

29%

Cost of goods sold

16.4m19.8m

Gross profit

35.4m47.1m

Gross profit Margin, %

68%70%

R&D expense

15.5m22.1m23.1m20.6m

General and administrative expense

20.8m25.1m72.3m64.3m

Operating expense total

36.3m47.2m95.4m84.9m

EBIT

(847.0k)(113.0k)(48.9m)(52.7m)

EBIT margin, %

(2%)0%(73%)(100%)

Interest expense

6.1m7.7m

Interest income

552.0k636.0k

Pre tax profit

(61.4m)(66.2m)

Income tax expense

Net Income

(9.6m)(8.9m)(61.4m)(66.2m)

Quarterly

USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

16.4m23.4m13.9m13.3m12.6m11.1m12.4m8.8m

Cost of goods sold

4.2m5.6m

Gross profit

12.3m17.8m

Gross profit Margin, %

75%76%

R&D expense

5.3m4.9m8.0m4.5m4.3m8.2m5.1m4.4m

General and administrative expense

6.1m7.6m33.6m12.3m17.9m16.2m13.7m14.6m

Operating expense total

11.5m12.5m41.6m16.9m22.2m24.4m18.8m19.0m

EBIT

781.0k5.3m(32.7m)(9.2m)(13.1m)(18.7m)(11.0m)(13.9m)

EBIT margin, %

5%23%(235%)(69%)(103%)(168%)(89%)(158%)

Interest expense

1.8m1.9m

Interest income

216.0k274.0k153.0k138.0k102.0k

Pre tax profit

(36.5m)(15.0m)(14.7m)(20.5m)(18.4m)(16.5m)

Income tax expense

Net Income

(1.5m)4.1m(36.5m)(15.0m)(14.7m)(20.5m)(18.4m)(16.5m)

Aquestive Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

9.2m17.4m60.6m49.3m

Accounts Receivable

10.8m6.2m6.5m

Prepaid Expenses

420.0k591.0k1.7m3.0m

Inventories

5.4m2.9m

Current Assets

23.3m28.2m74.2m68.3m

PP&E

15.1m13.5m12.2m9.7m

Total Assets

39.4m43.1m86.9m78.5m

Accounts Payable

6.6m9.6m20.4m12.3m

Short-term debt

4.6m

Current Liabilities

10.8m15.4m33.0m18.6m

Long-term debt

38.7m45.5m60.3m

Non-Current Liabilities

46.2m54.3m

Total Debt

38.7m45.5m4.6m60.3m

Total Liabilities

76.8m84.6m

Common Stock

11.2m12.7m25.0k34.0k

Preferred Stock

38.8m38.8m

Additional Paid-in Capital

1.5m71.4m124.3m

Retained Earnings

(108.7m)(120.1m)(61.4m)(130.5m)

Total Equity

(57.2m)(68.6m)10.1m(6.1m)

Debt to Equity Ratio

-0.7 x-0.7 x

Debt to Assets Ratio

1 x1.1 x

Financial Leverage

-0.7 x-0.6 x8.6 x-12.8 x

Quarterly

USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

16.5m10.6m64.0m39.9m22.2m20.9m35.5m

Accounts Receivable

9.4m6.6m7.5m

Prepaid Expenses

642.0k5.0m1.4m3.4m2.1m2.7m2.9m

Inventories

4.3m4.5m5.1m4.6m4.1m3.1m

Current Assets

30.4m26.6m77.4m56.0m39.1m38.1m51.1m

PP&E

12.8m12.8m12.2m11.6m10.9m10.4m9.1m

Total Assets

46.1m39.8m90.0m68.0m50.4m48.8m64.5m

Accounts Payable

11.0m16.5m12.3m19.1m20.0m14.2m10.3m

Short-term debt

1.7m1.1m2.8m6.9m550.0k609.0k

Current Liabilities

16.1m23.5m21.3m29.6m24.6m20.1m15.4m

Long-term debt

44.3m64.3m

Non-Current Liabilities

52.4m

Total Debt

46.0m1.1m2.8m6.9m550.0k65.0m

Total Liabilities

78.8m66.6m74.0m75.1m83.3m85.3m

Common Stock

15.0k20.0k25.0k25.0k25.0k25.0k34.0k

Additional Paid-in Capital

(26.5m)(6.6m)70.9m72.9m74.7m83.4m126.1m

Retained Earnings

4.1m(32.4m)(47.4m)(79.0m)(99.4m)(117.8m)(147.0m)

Total Equity

(22.4m)(38.9m)23.4m(6.1m)(24.7m)(34.5m)(20.8m)

Debt to Equity Ratio

-2.1 x

Debt to Assets Ratio

1 x

Financial Leverage

-2.1 x-1 x3.8 x-11.2 x-2 x-1.4 x-3.1 x

Aquestive Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(9.6m)(8.9m)(61.4m)(66.2m)

Depreciation and Amortization

3.8m3.8m3.2m2.9m

Accounts Receivable

(6.5m)4.7m(409.0k)(6.8m)

Inventories

(1.6m)(1.1m)(1.4m)2.6m

Accounts Payable

1.7m2.9m11.3m(7.9m)

Cash From Operating Activities

(8.2m)5.8m(13.0m)(60.2m)

Purchases of PP&E

(1.8m)(663.0k)

Capital Expenditures

(976.0k)(2.1m)

Cash From Investing Activities

190.0k(2.1m)(1.8m)(663.0k)

Long-term Borrowings

(50.0m)

Cash From Financing Activities

5.7m4.4m58.0m49.6m

Net Change in Cash

(2.3m)8.2m43.2m(11.3m)

Interest Paid

6.0m7.3m

Free Cash Flow

(9.2m)3.8m

Quarterly

USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(1.5m)4.1m(32.4m)(47.4m)(14.7m)(35.2m)(53.6m)(16.5m)

Depreciation and Amortization

915.0k940.0k1.7m2.5m749.0k1.5m2.2m887.0k

Accounts Receivable

(3.5m)(3.3m)(481.0k)(1.3m)(963.0k)(3.7m)(3.9m)3.7m

Inventories

(613.0k)165.0k(334.0k)(469.0k)304.0k794.0k1.3m(228.0k)

Accounts Payable

15.9m1.4m3.6m2.8m(3.3m)(1.8m)(5.6m)(3.6m)

Cash From Operating Activities

3.9m785.0k1.3m(10.2m)(17.7m)(34.8m)(49.6m)(13.6m)

Purchases of PP&E

(886.0k)(1.3m)(376.0k)(486.0k)(577.0k)(131.0k)

Capital Expenditures

(657.0k)(259.0k)

Cash From Investing Activities

(657.0k)(259.0k)(886.0k)(1.3m)(376.0k)(486.0k)(577.0k)(131.0k)

Long-term Borrowings

(550.0k)(50.0m)

Cash From Financing Activities

5.0m(1.4m)(7.2m)58.1m(2.6m)(3.1m)10.5m(37.0k)

Net Change in Cash

8.3m(891.0k)(6.7m)46.6m(20.7m)(38.4m)(39.7m)(13.8m)

Interest Paid

3.0m4.5m1.0m2.6m5.2m2.2m

Free Cash Flow

3.3m526.0k

Aquestive Therapeutics Ratios

USDY, 2020

EV/EBIT

-14.5 x

EV/CFO

-14.7 x

Financial Leverage

-3.1 x

Aquestive Therapeutics Operating Metrics

Q1, 2018

Doses of Suboxone Produced to Date

1.10 b

Patent Applications

75

Patents (US)

40

Patents Issued

200

Aquestive Therapeutics Employee Rating

2.944 votes
Culture & Values
3.3
Work/Life Balance
2.9
Senior Management
2.9
Salary & Benefits
3.6
Career Opportunities
3.0
Source